Last updated on August 2019

Study of Durvalumab + Tremelimumab Durvalumab and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy


Brief description of study

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Clinical Study Identifier: NCT03703297

Find a site near you

Start Over

Research Site

Osakasayama, Japan
1.93miles
  Connect »

Research Site

Sakai-shi, Japan
5.56miles
  Connect »